Effect of Salbutamol Valsartan Combined with Trimetazidine on Patients with Coronary Heart Disease and Chronic Heart Failure

JIANG Heng; ZHANG Min; XU Chencheng; DAI Guoming

doi:10.14033/j.cnki.cfmr.2023.34.008

Abstract：Objective:To analyze the effect of Salbutamol Valsartan combined with Trimetazidine on patients with coronary heart disease(CHD)and chronic heart failure(HF).Method:A total of 105 patients with CHD and chronic HF admitted to the Second People's Hospital of Changshu City from January 2019 to September 2022 were included in the study and divided into two groups according to the red and blue ball method,with 52 cases in the observation group and 53 cases in the control group.The control group was treated with Trimetazidine,and the observation group was treated with Salbutamol Valsartan on the basis of the control group.The efficacy,cardiac function myocardial injury exercise endurance and sleep quality of the two groups were compared.Result:The total effective rate of the observation group was higher than that in control group,the difference was statistically significant(P<0.05).The cardiac output(CO)and left ventricular ejection fraction(LVEF)of the observation group after treatment were higher than those of the control group,while the left ventricular end diastolic diameter(LVEDD)and left ventricular end-systolic dimension(LVESD)were lower than those of the control group,and the differences were statistically significant(P<0.05).The levels of creatine kinase(CK),creatine kinase isoenzymes(CK-MB),cardiac troponin I(cTnI)and brain natriuretic peptide(BNP)in the observation group after treatment were lower than those in the control group,and the differences were statistically significant(P<0.05).The 6 minute walk distance(6MWD)of the observation group after treatment was longer than that of the control group,and the Pittsburgh sleep quality index(PSQI)score was lower than that of the control group,the differences were statistically significant(P<0.05).Conclusion:Salbutamol Valsartan combined with Trimetazidine in the treatment of patients with CHD and chronic HF can improve cardiac function,inhibit myocardial injury,improve exercise endurance and improve sleep quality.